(Q30903645)

27 June 2017

title

Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development (English)

1 reference

27 June 2017

Kalle Sigfridsson

1

1 reference

27 June 2017

Anders J Lundqvist

series ordinal

2

1 reference

27 June 2017

Marie Strimfors

series ordinal

3

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Drug Development and Industrial Pharmacy

27 June 2017

published in

1 reference

27 June 2017

volume

35

1 reference

27 June 2017

issue

12

1 reference

27 June 2017

page(s)

1479-1486

1 reference

Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

Cyclodextrins: their future in drug formulation and delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

Excipient-drug interactions in parenteral formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

Top ten considerations in the development of parenteral emulsions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

Microemulsion-based media as novel drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

Dependence of area under the curve on proquazone particle size and in vitro dissolution rate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

An HPLC method to evaluate purity of a steroidal drug, loteprednol etabonate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

Pharmaceutical and analytical characterisation of (2R)-(3-amino-2-fluoropropyl)sulphinic acid, a GABAB receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

Nanosizing--oral formulation development and biopharmaceutical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

Preparation and characterization of intravenously injectable nimodipine nanosuspension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

Absorption of oral progesterone is influenced by vehicle and particle size

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03639040903025855

10.3109/03639040903025855

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference